| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Cidara Therapeutics, Inc.
13G
CDTX · 171757206
|
9.0% |
5/12/2025
Event 3/31/2025
|
|||
| Adage Capital Management, L.P. | 9.0% | ||||
| Robert Atchinson | 9.0% | ||||
| Phillip Gross | 9.0% | ||||
|
Ensysce Biosciences, Inc.
13G
ENSC · 293602504
|
5.3% |
5/12/2025
Event 3/31/2025
|
|||
| Adage Capital Management, L.P. | 5.3% | ||||
| Robert Atchinson | 5.3% | ||||
| Phillip Gross | 5.3% | ||||
|
Centessa Pharmaceuticals plc
13G
CNTA · 152309100
|
5.2% |
5/12/2025
Event 3/31/2025
|
|||
| Adage Capital Management, L.P. | 5.2% | ||||
| Robert Atchinson | 5.2% | ||||
| Phillip Gross | 5.2% | ||||
|
Traws Pharma, Inc.
13G
TRAW · 68232V884
|
6.5% |
5/12/2025
Event 3/31/2025
|
|||
| Adage Capital Management, L.P. | 6.5% | ||||
| Robert Atchinson | 6.5% | ||||
| Phillip Gross | 6.5% | ||||
|
UroGen Pharma Ltd.
13G/A
Amendment 2
URGN · M96088105
|
2.8% |
5/12/2025
Event 3/31/2025
|
|||
| Adage Capital Management, L.P. | 2.8% | ||||
| Robert Atchinson | 2.8% | ||||
| Phillip Gross | 2.8% | ||||
|
Aeva Technologies, Inc.
13G/A
Amendment 2
AEVA · 00835Q202
|
2.6% |
5/12/2025
Event 3/31/2025
|
|||
| Adage Capital Management, L.P. | 2.6% | ||||
| Robert Atchinson | 2.6% | ||||
| Phillip Gross | 2.6% | ||||
|
Protara Therapeutics, Inc.
13G/A
Amendment 1
TARA · 74365U107
|
0% |
5/12/2025
Event 3/31/2025
|
|||
| Adage Capital Management, L.P. | 0% | ||||
| Robert Atchinson | 0% | ||||
| Phillip Gross | 0% | ||||
|
Mereo BioPharma Group plc
13G/A
Amendment 2
MREO · 589492107
|
1.1% |
5/12/2025
Event 3/31/2025
|
|||
| Adage Capital Management, L.P. | 1.1% | ||||
| Robert Atchinson | 1.1% | ||||
| Phillip Gross | 1.1% | ||||
|
Lexeo Therapeutics, Inc.
13G/A
Amendment 2
LXEO · 52886X107
|
0.7% |
5/12/2025
Event 3/31/2025
|
|||
| Adage Capital Management, L.P. | 0.7% | ||||
| Robert Atchinson | 0.7% | ||||
| Phillip Gross | 0.7% | ||||
|
Abeona Therapeutics Inc.
13G/A
Amendment 9
ABEO · 00289Y206
|
8.8% |
5/12/2025
Event 3/31/2025
|
|||
| Adage Capital Management, L.P. | 8.8% | ||||
| Robert Atchinson | 8.8% | ||||
| Phillip Gross | 8.8% | ||||
|
ProQR Therapeutics N.V.
13G
PRQR · N71542109
|
9.3% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 9.3% | ||||
| Robert Atchinson | 9.3% | ||||
| Phillip Gross | 9.3% | ||||
|
Monopar Therapeutics
13G
MNPR · 61023L207
|
9.9% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 9.9% | ||||
| Robert Atchinson | 9.9% | ||||
| Phillip Gross | 9.9% | ||||
|
Immunic, Inc.
13G/A
Amendment 1
IMUX · 4525EP101
|
1.6% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 1.6% | ||||
| Robert Atchinson | 1.6% | ||||
| Phillip Gross | 1.6% | ||||
|
Karyopharm Therapeutics Inc.
13G
KPTI · 48576U106
|
5.2% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 5.2% | ||||
| Robert Atchinson | 5.2% | ||||
| Phillip Gross | 5.2% | ||||
|
enGene Holdings Inc.
13G/A
Amendment 1
ENGN · 29286M105
|
3.0% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 3.0% | ||||
| Robert Atchinson | 3.0% | ||||
| Phillip Gross | 3.0% | ||||
|
Lexeo Therapeutics, Inc.
13G/A
Amendment 1
LXEO · 52886X107
|
6.7% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 6.7% | ||||
| Robert Atchinson | 6.7% | ||||
| Phillip Gross | 6.7% | ||||
|
UroGen Pharma Ltd.
13G/A
Amendment 1
URGN · M96088105
|
6.9% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 6.9% | ||||
| Robert Atchinson | 6.9% | ||||
| Phillip Gross | 6.9% | ||||
|
Dynamix Corp
13G
DYNC · G2949D104
|
8.1% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 8.1% | ||||
| Robert Atchinson | 8.1% | ||||
| Phillip Gross | 8.1% | ||||
|
EyePoint Pharmaceuticals, Inc.
13G/A
Amendment 3
EYPT · 30233G209
|
8.4% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 8.4% | ||||
| Robert Atchinson | 8.4% | ||||
| Phillip Gross | 8.4% | ||||
|
Aligos Therapeutics, Inc.
13G/A
Amendment 1
ALGS · 01626L204
|
9.4% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 9.4% | ||||
| Robert Atchinson | 9.4% | ||||
| Phillip Gross | 9.4% | ||||
|
Zevra Therapeutics, Inc.
13G
ZVRA · 488445206
|
6.8% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 6.8% | ||||
| Robert Atchinson | 6.8% | ||||
| Phillip Gross | 6.8% | ||||
|
Fulcrum Therapeutics, Inc.
13G
FULC · 359616109
|
5.6% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 5.6% | ||||
| Robert Atchinson | 5.6% | ||||
| Phillip Gross | 5.6% | ||||
|
Seadrill Ltd
13G
SDRL · G7997W102
|
5.3% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 5.3% | ||||
| Robert Atchinson | 5.3% | ||||
| Phillip Gross | 5.3% | ||||
|
Aclaris Therapeutics, Inc.
13G
ACRS · 00461U105
|
9.0% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 9.0% | ||||
| Robert Atchinson | 9.0% | ||||
| Phillip Gross | 9.0% | ||||
|
Sitio Royalties Corp.
13G
STR · 82983N108
|
7.9% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 7.9% | ||||
| Robert Atchinson | 7.9% | ||||
| Phillip Gross | 7.9% | ||||
|
Protara Therapeutics, Inc.
13G
TARA · 74365U107
|
6.6% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 6.6% | ||||
| Robert Atchinson | 6.6% | ||||
| Phillip Gross | 6.6% | ||||
|
Janux Therapeutics, Inc.
13G
JANX · 47103J105
|
5.3% |
2/12/2025
Event 12/31/2024
|
|||
| Adage Capital Management, L.P. | 5.3% | ||||
| Robert Atchinson | 5.3% | ||||
| Phillip Gross | 5.3% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.